The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Abstract
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours 1,2. We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are prevalent in melanoma-in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT trial, ClinicalTrials.gov identifier NCT02410733). We report here data from an exploratory interim analysis that show that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediates durable objective responses in checkpoint-inhibitor (CPI)-experienced patients with unresectable melanoma. Clinical responses are accompanied by the induction of strong CD4+ and CD8+ T cell immunity against the vaccine antigens. The antigen-specific cytotoxic T-cell responses in some responders reach magnitudes typically reported for adoptive T-cell therapy, and are durable. Our findings indicate that RNA-LPX vaccination is a potent immunotherapy in patients with CPI-experienced melanoma, and suggest the general utility of non-mutant shared tumour antigens as targets for cancer vaccination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging results.”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [18]
In the citing paper
“Previous studies have demonstrated that the use of BNT111 alone or in combination with PD-1 antibody can activate tumor antigen-specific CD4+ and CD8+ T cells and elicit durable immune responses.345,350–352”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [345]
In the citing paper
“For example, FixVac, which was developed based on the RNA-LPX formulation, is a systemic mRNA vaccine encoding four non-mutated antigens of melanoma200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“After the eighth immunization, more than 75% of patients generated immune responses against at least one tumour-associated antigen, and CD8+ T cells played a major role in high-magnitude T cell responses200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“Moreover, a combination of FixVac/anti-programmed cell death protein 1 (PD1) antibody augmented the antitumour effect of FixVac, resulting in a >35% tumour regression rate in immune checkpoint inhibitor-experienced patients200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“The interim analysis from the phase I trial (NCT02410733) showed that the metabolic activity of the spleen increased post the sixth immunization, indicating targeted delivery of FixVac and activation of resident immune cells200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationMiXCR: software for comprehensive adaptive immunity profiling
Bolotin, D. A., Poslavskii, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,730
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Cited by
Sorted by citations
Items 101–200 of 1,000
Cancer vaccines: current status and future directions
Zhou, Y., Wei, Y., Tian, X., & Wei, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01670-w · Cited by 121
Haghighi, E., Abolmaali, S. S., Dehshahri, A., Shaegh, S. A. M., Azarpira, N., & Tamaddon, A. M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02972-w · Cited by 125
Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections
Abramson, A., Kirtane, A. R., Shi, Y., Zhong, G., Collins, J. E., Tamang, S. M., Ishida, K., Hayward, A. M., Wainer, J., Rajesh, N. U., et al. (2022) · Matter · doi:10.1016/j.matt.2021.12.022 · Cited by 110
mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalıkhani-Hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 111
‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA
Parry, P. I., Lefringhausen, A., Turni, C., Neil, C., Cosford, R., Hudson, N. J., & Gillespie, J. (2023) · Biomedicines · doi:10.3390/biomedicines11082287 · Cited by 109
Chen, Z., Tian, Y., Yang, J., Wu, F., Liu, S., Cao, W., Xu, W., Hu, T., Siegwart, D. J., & Xiong, H. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c09143 · Cited by 108
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Wang, M., Yu, F., & Zhang, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02214-5 · Cited by 110
Lipid Nanoparticle Technologies for Nucleic Acid Delivery: A Nanoarchitectonics Perspective
Ferhan, A. R., Park, S.-H., Park, H., Tae, H., Jackman, J. A., & Cho, N. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202203669 · Cited by 103
RNA-based therapies: A cog in the wheel of lung cancer defense
Κhan, P., Siddiqui, J. A., Lakshmanan, I., Ganti, A. K., Salgia, R., Jain, M., Batra, S. K., & Nasser, M. W. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01338-2 · Cited by 104
Deciphering the immunopeptidome in vivo reveals new tumour antigens
Jaeger, A. M., Stopfer, L. E., Ahn, R., Sanders, E. A., Sandel, D. A., Freed-Pastor, W. A., Rideout, W. M., Naranjo, S., Fessenden, T. B., Nguyen, K. B., et al. (2022) · Nature · doi:10.1038/s41586-022-04839-2 · Cited by 102
Immunogenic Cell Death-Based Cancer Vaccines
Jin, M.-Z., & Wang, X.-P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697964 · Cited by 99
“The study showed that the RNA-LPX vaccine alone or combined with ICBs enhanced antitumor immunity, resulted in a better therapeutic response and confirmed that TAAs-based cancer vaccine could be utilized in immunotherapy (15).”
BackgroundThe Origin and Immune Recognition of Tumor-Specific Antigens
Apavaloaei, A., Hardy, M., Thibault, P., & Perreault, C. (2020) · Cancers · doi:10.3390/cancers12092607 · Cited by 95
3D Printing Scaffold Vaccine for Antitumor Immunity
Zhang, Y., Xu, J., Fei, Z., Dai, H., Fan, Q., Yang, Q., Chen, Y., Wang, B., & Wang, C. (2021) · Advanced Materials · doi:10.1002/adma.202106768 · Cited by 99
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 107
The advances of adjuvants in mRNA vaccines
Xie, C., Yao, R., & Xia, X. (2023) · npj Vaccines · doi:10.1038/s41541-023-00760-5 · Cited by 102
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2
Au, L., Fendler, A., Shepherd, S. T. C., Rzeniewicz, K., Cerrone, M., Byrne, F., Carlyle, E., Edmonds, K., Rosario, L. D., Shon, J. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01387-6 · Cited by 98
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 98
Li, X., Qi, J., Wang, J., Hu, W., Zhou, W., Wang, Y., & Li, T. (2024) · Theranostics · doi:10.7150/thno.84291 · Cited by 100
Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology
Bockamp, E., Rosigkeit, S., Siegl, D., & Schuppan, D. (2020) · Cells · doi:10.3390/cells9092102 · Cited by 96
Evolution of nanomedicine formulations for targeted delivery and controlled release
Puri, S., Mazza, M., Roy, G., England, R., Zhou, L., Nourian, S., & Subramony, J. A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114962 · Cited by 94
Cancer vaccines and the future of immunotherapy
Pail, O., Lin, M. J., Anagnostou, T., Brown, B. D., & Brody, J. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00553-7 · Cited by 98
Type I IFN activating type I dendritic cells for antitumor immunity
Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2564 · Cited by 91
Chemical Modifications of mRNA Ends for Therapeutic Applications
Warminski, M., Mamot, A., Depaix, A., Kowalska, J., & Jemielity, J. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00442 · Cited by 91
HNSCC: Tumour Antigens and Their Targeting by Immunotherapy
Witzleben, A. V., Wang, C., Laban, S. A., Savelyeva, N., & Ottensmeier, C. H. H. (2020) · Cells · doi:10.3390/cells9092103 · Cited by 93
Trained immunity: Target for prophylaxis and therapy
Ziogas, A., Bruno, M., van der Meel, R., Mulder, W. J. M., & Netea, M. G. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.015 · Cited by 90
Lymph node-targeting nanovaccines for cancer immunotherapy
Wang, Q., Wang, Z., Sun, X., Jiang, Q., Sun, B., He, Z., Zhang, S., Luo, C., & Sun, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.015 · Cited by 90
mRNA nanodelivery systems: targeting strategies and administration routes
Yuan, M., Han, Z., Liang, Y., Sun, Y., He, B., Chen, W., & Fan, L. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00425-3 · Cited by 98
Recent progress in mRNA cancer vaccines
Yao, R., Xie, C., & Xia, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2307187 · Cited by 91
Adjuvant physiochemistry and advanced nanotechnology for vaccine development
Ren, H., Jia, W., Xie, Y., Yu, M., & Chen, Y. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00848c · Cited by 91
Eliciting antitumor immunity via therapeutic cancer vaccines
Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 104
Pandey, P. R., Young, K. H., Kumar, D., & Jain, N. K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01528-6 · Cited by 89
The MHC Motif Atlas: a database of MHC binding specificities and ligands
Tadros, D. M., Eggenschwiler, S., Racle, J., & Gfeller, D. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac965 · Cited by 90
Li, J., Xiao, Z., Wang, D., Jia, L., Nie, S., Zeng, X., & Hu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01844-5 · Cited by 95
Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics
Ang, M. J. Y., Chan, S. Y., Goh, Y. Y., Luo, Z., Lau, J. W., & Liu, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113907 · Cited by 87
Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo
Luo, Z., Lin, Y., Meng, Y., Li, M., Ren, H., Shi, H., Cheng, Q., & Wei, T. (2024) · ACS Nano · doi:10.1021/acsnano.4c09902 · Cited by 88
Liu, L., Chen, J., Zhang, H., Ye, J., Moore, C., Lu, C., Fang, Y., Fu, Y., & Li, B. (2022) · Nature Cancer · doi:10.1038/s43018-022-00352-7 · Cited by 86
Biomimetic cell-derived nanocarriers in cancer research
Soprano, E., Polo, E., Pelaz, B., & del Pino, P. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01748-4 · Cited by 84
Vaccines for immunoprevention of cancer
Enokida, T., Moreira, A., & Bhardwaj, N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146956 · Cited by 85
Wang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 85
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Bansal, D., Reimers, M. A., Knoche, E. M., & Pachynski, R. K. (2021) · Cancers · doi:10.3390/cancers13020334 · Cited by 81
Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects
Gupta, M., Wahi, A., Sharma, P., Nagpal, R., Raina, N., Kaurav, M., Bhattacharya, J., Oliveira, S. M. R., Dolma, K. G., Paul, A. K., et al. (2022) · Vaccines · doi:10.3390/vaccines10122011 · Cited by 80
The future of affordable cancer immunotherapy
Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 81
mRNA Cancer Vaccines: Construction and Boosting Strategies
Liu, X., Huang, P., Yang, R., & Deng, H. (2023) · ACS Nano · doi:10.1021/acsnano.3c05635 · Cited by 79
Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy
Isser, A., Livingston, N. K., & Schneck, J. P. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120584 · Cited by 77
Therapeutic strategies to remodel immunologically cold tumors
Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 79
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 78
Pallares, R. M., Barmin, R. A., Wang, A., Kiessling, F. M., & Lammers, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113991 · Cited by 81
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Inagaki, M., Abe, N., Li, Z., Nakashima, Y., Acharyya, S., Ogawa, K., Kawaguchi, D., Hiraoka, H., Banno, A., Meng, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38244-8 · Cited by 80
Naidu, G. S., Rampado, R., Sharma, P., Ezra, A., Kundoor, G. R., Breier, D., & Peer, D. (2025) · ACS Nano · doi:10.1021/acsnano.4c18636 · Cited by 77
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 81
mRNA vaccine against malaria tailored for liver-resident memory T cells
Ganley, M., Holz, L. E., Minnell, J. J., de Menezes, M. N., Burn, O. K., Poa, K. C. Y., Draper, S. L., English, K., Chan, S. T. S., Anderson, R. J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01562-6 · Cited by 77
Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy
Lee, D., Huntoon, K. M., Wang, Y., Jiang, W., & Kim, B. Y. S. (2021) · Advanced Materials · doi:10.1002/adma.202007576 · Cited by 74
Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines
Rinoldi, C., Zargarian, S. S., Nakielski, P., Li, X., Liguori, A., Petronella, F., Presutti, D., Wang, Q., Costantini, M., Sio, L. D., et al. (2021) · Small Methods · doi:10.1002/smtd.202100402 · Cited by 78
RNA Therapeutics - Research and Clinical Advancements
Feng, R., Patil, S., Zhao, X., Miao, Z., & Qian, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.710738 · Cited by 75
Janes, M. E., Gottlieb, A. P., Park, K. S., Zhao, Z., & Mitragotri, S. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10588 · Cited by 77
Lei, J., Qi, S., Yu, X., Gao, X., Yang, K., Zhang, X., Cheng, M., Bai, B., Feng, Y., Lu, M., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202318515 · Cited by 74
Cancer/testis antigens: from serology to mRNA cancer vaccine
Fan, C., Qu, H., Wang, X., Sobhani, N., Wang, L., Liu, S., Xiong, W., Zeng, Z., & Li, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.016 · Cited by 72
Haabeth, O. A. W., Lohmeyer, J. J. K., Sallets, A., Blake, T. R., Sagiv-Barfi, I., Czerwinski, D. K., McCarthy, B., Powell, A. E., Wender, P. A., Waymouth, R. M., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00361 · Cited by 74
The potential of long noncoding RNA therapies
Mercer, T. R., Munro, T. P., & Mattick, J. S. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.01.008 · Cited by 72
Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities
Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 74
Delivery of therapeutic oligonucleotides in nanoscale
Wu, L., Zhou, W., Lin, L., Chen, A., Feng, J. C., Qu, X., Zhang, H., & Yue, J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.038 · Cited by 72
Cancer Vaccines: Promising Therapeutics or an Unattainable Dream
Donninger, H., Li, C., Eaton, J. W., & Yaddanapudi, K. (2021) · Vaccines · doi:10.3390/vaccines9060668 · Cited by 74
Engineering nanomaterial physical characteristics for cancer immunotherapy
Lee, D., Huntoon, K. M., Lux, J., Kim, B. Y. S., & Jiang, W. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00047-3 · Cited by 71
Dolina, J. S., Lee, J., Brightman, S. E., McArdle, S., Hall, S. M., Thota, R. R., Zavala, K. S., Lanka, M., Premlal, A. L. R., Greenbaum, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164258 · Cited by 68
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications
Yan, Y., Liu, S., Wen, J., He, Y., Duan, C., Nabavi, N., Ashrafizadeh, M., Sethi, G., Liu, L., & Ma, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02463-y · Cited by 71
mRNA: A promising platform for cancer immunotherapy
Kong, B., Kim, Y., Kim, E. H., Suk, J. S., & Yang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114993 · Cited by 74
An iPSC-derived exosome-pulsed dendritic cell vaccine boosts antitumor immunity in melanoma
Wang, R., Zhu, T., Hou, B., & Huang, X. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.005 · Cited by 66
Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism
Li, Z., Amaya, L., Pi, R., Wang, S. K., Ranjan, A., Waymouth, R. M., Blish, C. A., Chang, H. Y., & Wender, P. A. (2023) · Nature Communications · doi:10.1038/s41467-023-42672-x · Cited by 65
Supramolecular assembly boosting the phototherapy performances of BODIPYs
Dai, Y., Sun, J., Zhang, X., Zhao, J., Yang, W., Zhou, J., Gao, Z., Wang, Q., Yu, F., & Wang, B. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216054 · Cited by 64
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 64
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 65
Qiu, K., Duan, X., Mao, M., Song, Y., Rao, Y., Cheng, D., Feng, L., Shao, X., Jiang, C., Huang, H., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00733-8 · Cited by 63
Delivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 62
Cancer vaccines: platforms and current progress
Lei, W., Zhou, K., Lei, Y., Qiu, L., & Zhu, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00241-8 · Cited by 66
Clinical development of therapeutic mRNA applications
Żak, M. M., & Zangi, L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.034 · Cited by 68
Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies
Li, S., Simoni, Y., Zhuang, S., Gabel, A. M., Ma, S., Chee, J., Islas, L., Cessna, A., Creaney, J., Bradley, R. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025570118 · Cited by 61
Mørk, S. K., Kadivar, M., Bol, K. F., Draghi, A., Westergaard, M. C. W., Skadborg, S. K., Overgaard, N. H., Sørensen, A. B., Rasmussen, I. S., Andreasen, L. V., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2023255 · Cited by 62
RNA modification in mRNA cancer vaccines
Mei, Y., & Wang, X. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01020-5 · Cited by 62
Tang, X., Zhang, J., Sui, D., Yang, Q., Wang, T., Xu, Z., Li, X., Gao, X., Yan, X., Liu, X., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.008 · Cited by 61
RNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 64
Ballotti, R., Chéli, Y., & Bertolotto, C. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01290-7 · Cited by 63
Supabphol, S., Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1896702 · Cited by 60
Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity
Meng, F., Li, L., Zhang, Z., Lin, Z., Zhang, J., Song, X., Xue, T., Xing, C., Liang, X., & Zhang, X. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12289 · Cited by 59
Trivedi, V., Yang, C., Klippel, K., Yegorov, O., Roemeling, C. A. V., Hoang-Minh, L., Fenton, G. A., Ogando‐Rivas, E., Castillo, P., Moore, G. L., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01281-z · Cited by 59
Chiral polypeptide hydrogels regulating local immune microenvironment and anti-tumor immune response
Ding, J., Wang, T., Lin, Z., Li, Z., Yang, J., Li, F., Rong, Y., Chen, X., & He, C. (2025) · Nature Communications · doi:10.1038/s41467-025-56137-w · Cited by 60
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan, Y., Gao, F., Chang, Y., Zhao, Q., & He, X. (2023) · Biomarker Research · doi:10.1186/s40364-023-00449-w · Cited by 60
Graewert, M. A., Wilhelmy, C., Bacic, T., Schumacher, J., Blanchet, C. E., Meier, F., Drexel, R., Welz, R., Kolb, B., Bartels, K., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42274-z · Cited by 58
Self-citationThe paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Emerging small molecule-engineered hybrid nanomedicines for cancer therapy
Chen, Y., Zhao, T., Bai, M., Gu, T., Sun, J., He, Z., Zhang, S., & Luo, C. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135160 · Cited by 57
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 58
Application of lipid-based nanoparticles in cancer immunotherapy
Zhang, Z., Yao, S., Hu, Y., Zhao, X. B., & Lee, R. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967505 · Cited by 58
Lipid-Nucleic Acid Complexes: Physicochemical Aspects and Prospects for Cancer Treatment
Gaspar, R., Coelho, F., & Silva, B. F. B. (2020) · Molecules · doi:10.3390/molecules25215006 · Cited by 59
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 60
An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants
Tai, W., Feng, S., Chai, B., Lu, S., Zhao, G., Chen, D., Yu, W., Ren, L., Shi, H., Lü, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38751-8 · Cited by 58
Tockary, T. A., Abbasi, S., Matsui-Masai, M., Hayashi, A., Yoshinaga, N., Boonstra, E., Wang, Z., Fukushima, S., Kataoka, K., & Uchida, S. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214320120 · Cited by 56
Li, X., Li, J., Wei, J., Du, W., Su, C., Shen, X., Zhao, A., & Xu, M. (2025) · MedComm · doi:10.1002/mco2.70414 · Cited by 60
Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy
Kim, Y., Choi, J., Kim, E. H., Park, W., Jang, H., Jang, Y., Chi, S., Kweon, D., Lee, K., Kim, S. H., et al. (2024) · Advanced Science · doi:10.1002/advs.202309917 · Cited by 57
mRNA vaccine designs for optimal adjuvanticity and delivery
Mochida, Y., & Uchida, S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2333123 · Cited by 57
Metadata
- Authors
- Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H., Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitkreuz, A., Tolliver, C., Caspar, J., Quinkhardt, J., Hebich, L., Stein, M., Hohberger, A., Vogler, I., Liebig, I., Renken, S., Sikorski, J., Leierer, M., Müller, V., Mitzel-Rink, H., Miederer, M., Huber, C., Grabbe, S., Utikal, J., Pinter, A., Kaufmann, R., Hassel, J. C., Loquai, C., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- University Hospital Frankfurt (DE)
- ORCID
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 585
- Issue
- 7823
- Pages
- 107-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3046115489
- Cited by
- 1,052
- References
- 36
- Citations by year
- 2026: 140 · 2025: 204 · 2024: 191 · 2023: 190 · 2022: 174 · 2021: 131 · 2020: 21
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- RNA vaccines, melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, tumor-associated antigens, cancer immunotherapy, CD4+ T cells, CD8+ T cells, cytotoxic T lymphocyte response
- MeSH terms
- Antigens, Neoplasm, Antineoplastic Agents, Combined Modality Therapy, Humans, Melanoma, Neoplasm Staging, RNA, Neoplasm, T-Lymphocytes, T-Lymphocytes, Cytotoxic, Vaccination, Cancer Vaccines, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
